Literature DB >> 18484598

Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency?

Chris Frost1, Michael G Kenward, Nick C Fox.   

Abstract

It is well known that the statistical power of randomized controlled trials with a continuous outcome can be increased by using a pre-randomization baseline measure of the outcome variable as a covariate in the analysis. For a trial where the outcome measure is a rate, for example in a therapeutic trial in Alzheimer's disease, the relevant covariate is a pre-randomization measure of that rate. Obtaining this requires separating the total follow-up period into two periods. In the first 'run-in' period all patients would be 'off-treatment' to facilitate the calculation of baseline atrophy rates. In the second 'on-treatment' period half of the patients, selected at random, would be switched onto active treatment with the others remaining off treatment. In this paper we use linear mixed models to establish a methodological framework that is then used to assess the extent to which such designs can increase statistical power. We illustrate our methodology with two examples. The first is a design with three evenly spaced time points analysed with a standard random slopes model. The second is a model for repeated 'direct' measures of changes used for the analysis of imaging studies with visits at multiple time points. We show that run-in designs can materially reduce sample size provided that true between-subject variability in rates is large relative to measurement error.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18484598     DOI: 10.1002/sim.3280

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  15 in total

1.  Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment.

Authors:  J M Schott; J W Bartlett; J Barnes; K K Leung; S Ourselin; N C Fox
Journal:  Neurobiol Aging       Date:  2010-08       Impact factor: 4.673

2.  Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease.

Authors:  Chengjie Xiong; Gerald van Belle; J Philip Miller; John C Morris
Journal:  Clin Trials       Date:  2011-02       Impact factor: 2.486

3.  Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity.

Authors:  Roos J Jutten; Sietske A M Sikkes; Wiesje M Van der Flier; Philip Scheltens; Pieter Jelle Visser; Betty M Tijms
Journal:  Neurology       Date:  2021-06-01       Impact factor: 11.800

4.  An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.

Authors:  Sigurd D Süssmuth; Salman Haider; G Bernhard Landwehrmeyer; Ruth Farmer; Chris Frost; Giovanna Tripepi; Claus A Andersen; Marco Di Bacco; Claudia Lamanna; Enrica Diodato; Luisa Massai; Daniela Diamanti; Elisa Mori; Letizia Magnoni; Jens Dreyhaupt; Karin Schiefele; David Craufurd; Carsten Saft; Monika Rudzinska; Danuta Ryglewicz; Michael Orth; Sebastian Brzozy; Anna Baran; Giuseppe Pollio; Ralph Andre; Sarah J Tabrizi; Borje Darpo; Goran Westerberg
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

5.  Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design.

Authors:  Maria Soto; Sandrine Andrieu; Fati Nourhashemi; Pierre Jean Ousset; Clive Ballard; Philippe Robert; Bruno Vellas; Constantine G Lyketsos; Paul B Rosenberg
Journal:  Int Psychogeriatr       Date:  2014-09-16       Impact factor: 3.878

Review 6.  Epidemiological methods in diarrhoea studies--an update.

Authors:  Wolf-Peter Schmidt; Benjamin F Arnold; Sophie Boisson; Bernd Genser; Stephen P Luby; Mauricio L Barreto; Thomas Clasen; Sandy Cairncross
Journal:  Int J Epidemiol       Date:  2011-12       Impact factor: 7.196

7.  MIRIAD--Public release of a multiple time point Alzheimer's MR imaging dataset.

Authors:  Ian B Malone; David Cash; Gerard R Ridgway; David G MacManus; Sebastien Ourselin; Nick C Fox; Jonathan M Schott
Journal:  Neuroimage       Date:  2012-12-28       Impact factor: 6.556

8.  Randomized controlled trials: who fails run-in?

Authors:  Judy R Rees; Leila A Mott; Elizabeth L Barry; John A Baron; Jane C Figueiredo; Douglas J Robertson; Robert S Bresalier; Janet L Peacock
Journal:  Trials       Date:  2016-07-29       Impact factor: 2.279

9.  Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment.

Authors:  Peter Kosa; Danish Ghazali; Makoto Tanigawa; Chris Barbour; Irene Cortese; William Kelley; Blake Snyder; Joan Ohayon; Kaylan Fenton; Tanya Lehky; Tianxia Wu; Mark Greenwood; Govind Nair; Bibiana Bielekova
Journal:  Front Neurol       Date:  2016-08-15       Impact factor: 4.003

10.  Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge.

Authors:  David M Cash; Chris Frost; Leonardo O Iheme; Devrim Ünay; Melek Kandemir; Jurgen Fripp; Olivier Salvado; Pierrick Bourgeat; Martin Reuter; Bruce Fischl; Marco Lorenzi; Giovanni B Frisoni; Xavier Pennec; Ronald K Pierson; Jeffrey L Gunter; Matthew L Senjem; Clifford R Jack; Nicolas Guizard; Vladimir S Fonov; D Louis Collins; Marc Modat; M Jorge Cardoso; Kelvin K Leung; Hongzhi Wang; Sandhitsu R Das; Paul A Yushkevich; Ian B Malone; Nick C Fox; Jonathan M Schott; Sebastien Ourselin
Journal:  Neuroimage       Date:  2015-08-11       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.